THAR: Tharimmune Inc Company Value to Net Income
Tharimmune, Inc. (THAR) develops specific antibodies to combat tumors and autoimmune pathologies, leveraging patented technologies and a debt-free balance sheet. This daily price chart on GURU.Markets shows that the multiple is -18.40. The business operates within the US legal framework, which mitigates external political risks. However, the company faces intense pressure from pharma behemoths that possess colossal resources for expansion.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_THAR_-_Tharimmune-Inc._-_PE-Multiple "THAR: tharimmune.com Price to Earnings Ratio 02/21/2024 - 02/18/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Tharimmune Corp (THAR)
- share price and expert price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Tharimmune, Inc.|THAR - Long-Term Debt to Capital|Current Liabilities to Capital Tharimmune Corporation|THAR - Company Total Debt|Debt to Book Capital Tharimmune, Inc.|THAR - Company Long-Term Debts|Company Short-Term Loans and Borrowings Tharimmune|Quick Ratio tharimmune.com
- company profitability and valuation multiples indicators:
THAR - Company Net Income|Expected Net Income Tharimmune, Inc.|THAR - P/E Multiple|Market Cap to Projected Earnings Tharimmune Inc|THAR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Tharimmune, Inc.|THAR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Tharimmune|THAR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth tharimmune.com|THAR - Earnings per share growth in current year|Projected earnings per share growth rate for next year Tharimmune, Inc.
- issuer revenue and sales details:
General company analysis:tharimmune.com, THAR
This ratio serves as a key filter during asset stress testing, allowing for the determination of the overpayment level per unit of net profit. The ratio of market capitalization to annual income reflects investor expectations, while the target P/E of Tharimmune, Inc. (THAR) demonstrates the extent to which the valuation of Tharimmune, Inc. (THAR) is subject to pressure from pharma behemoths dominating the cancer immunotherapy sector.
Key competitors
ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Y-mAbs Corp YMAB|Price to Earnings Ratio AURA (Aura Biosciences, Inc.)|Market Price to Net Income Ratio CADL|P/E Multiple ARAY (Accuray)|Company Value to Net Income SLS|Actuate Therapeutics, Inc - P/E Multiple|CTOR - P/E Multiple|tuhurabio.com (HURA) - Price to Earnings Ratio|protaratx.com - Company Value to Net Income|FATE (Fate Therapeutics) - P/E Multiple|Aadi Bio (WHWK) - Business Payback Period|Price to Earnings Ratio TScan Therapeutics (TCRX)|Price to Earnings Ratio championsoncology.com CSBR|Price to Earnings Ratio XBiotech XBIT|CVM - Price to Earnings Ratio|OSTX: Price to Earnings Ratio|RADX - P/E Multiple|artivabio.com (ARTV) - Price to Earnings Ratio|Price to Earnings Multiple ANL|VERU (Veru Inc.) - P/E Multiple|Market Cap to Earnings tempesttx.com TPST|Price to Earnings Ratio XLO (Xilio Therapeutics, Inc.)|RENB (renovarobio.com) - Company Value to Net Income|P/E Multiple MURA (Mural Oncology)|Business Payback Period Kairos Pharma Limited (KAPA)|OKUR - Price to Earnings Ratio|GDTC (CytoMed Therapeutics) - Price to Earnings Multiple|CRIS: P/E Multiple|Price to Earnings Ratio Apollomics|Price to Earnings Ratio ADVB|Genprex Inc (GNPX) - Business Payback Period|Price to Earnings Ratio CLDI (Calidi Biotherapeutics)|Market Price to Net Income Ratio SBFM|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|Company Value to Net Income SLRX|Purple Biotech Corp - P/E Multiple|AONC - P/E Multiple|BeiGene, Ltd. (BGNE) - Price to Earnings Ratio|checkpointtx.com - Company Value to Net Income|ELEV (Elevation Oncology) - P/E Multiple|Price to Earnings Ratio iCAD Corp (ICAD)|P/E Multiple IKNA|P/E Multiple Notable Labs Corp (NTBL)|Price to Earnings Ratio Viracta Therapeutics, Inc. VIRX|MOR: Price to Earnings Multiple|NAYA Biosciences Inc. - P/E Multiple|Ascentage Pharma Group International (AAPGV) - Price to Earnings Ratio
